Clinical trials: Secondary Resistance
Metastatic Castration-Resistant Prostate Cancer
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of the phase 2 study is to determine whether Onvansertib is safe and tolerable in adult participants with Metastatic Castration-Resistant Prostate Cancer who have disease progression while receiving abiraterone…
- Trial name
- NCT03414034
- Testing
- Onvansertib, Abiraterone, Prednisone
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Cardiff Oncology
Prostate Cancer
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
The purpose of this study is to compare galeterone to enzalutamide in men expressing androgen receptor spice variant-7 mRNA (AR-V7) in metastatic (M1) castrate resistant prostate cancer (CRPC).
- Trial name
- ARMOR3-SV (NCT02438007)
- Testing
- Galeterone, Enzalutamide
- Where
- 117 sites in United States, Australia and 6 more
- Volunteers
- 953 people
- Sponsor
- LTN PHARMACEUTICALS, INC.
Cancer, Prostate Cancer
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase 1/2 multicenter, dose determining, open-label study of ADXS31-142 monotherapy and a combination of ADXS31-142 and pembrolizumab (MK-3475) in participants with metastatic castration-resistant prostate cancer.
- Trial name
- NCT02325557
- Testing
- ADXS31-142, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- Advaxis, Inc.
Prostate Cancer
Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability
The purpose of this study is to characterize the tolerability profiles of enzalutamide and abiraterone acetate (with prednisone) -with specific focus on central nervous system (CNS) tolerability-and quality of life (QoL) after…
- Trial name
- REAAcT (NCT02663193)
- Testing
- No Intervention
- Where
- 20 sites in United States
- Volunteers
- 108 people
- Sponsor
- Janssen Scientific Affairs, LLC
PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Clinical Evaluation of 177Lu-PSMA-VG01 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer （mCRPC）
This is a phase I clinical trial conducted in participants with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT07660211
- Testing
- 177Lu-PSMA-VG01
- Where
- China
- Volunteers
- 10 people
- Sponsor
- VitsGen Therapeutics Inc.
Bone Metastatic Castration-resistant Prostate Cancer
A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones
In this study researcher want to gain more information on how the study drug (radium-223) is distributed in the bone, particularly in the tumor free bone in participants with prostate cancer.
- Trial name
- NCT04521361
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 12 sites in Austria, France and 4 more
- Volunteers
- 46 people
- Sponsor
- Bayer
Advanced Solid Tumors
A Study of ASP1951 in Subjects With Advanced Solid Tumors
The primary purpose of this study is to evaluate the tolerability and safety profile of ASP1951 when administered as a single agent and in combination with pembrolizumab in participants with locally advanced (unresectable) or…
- Trial name
- NCT03799003
- Testing
- ASP1951, pembrolizumab
- Where
- 32 sites in United States, Canada and 2 more
- Volunteers
- 119 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostatic Neoplasms, Castration-Resistant
Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to find and evaluate the recommended Phase 2 dose (RP2D) of JNJ-64041809, a live attenuated double deleted (LADD) Listeria monocytogenes (bacteria in which two virulence genes, which encode molecules…
- Trial name
- NCT02625857
- Testing
- JNJ-64041809 (Cohort 1A and 1B), JNJ-64041809 (Cohort 2A and 2B)
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer
Multicenter open label, uncontrolled study that enrolled men with metastatic castrate resistant prostate cancer previously treated with sipuleucel-T in the androgen dependent setting in the Dendreon P-11 study.
- Trial name
- mCRPC (NCT01338012)
- Testing
- sipuleucel-T
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Dendreon
Metastatic Castration-resistant Prostate Cancer
A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
An open-label, multi-center, Phase 1/2 study to determine the safety, tolerability, and feasibility of dosing adult patients with mCRPC with genetically modified autologous T-cells (TmPSMA-02) engineered to express a CAR capable…
- Trial name
- NCT05489991
- Testing
- TmPSMA-02
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Tceleron Therapeutics, Inc.
Breast Cancer
A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)
Some human epidermal growth factor receptor 2 (HER-2) breast cancer patients do not respond or become resistant to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug.
- Trial name
- NCT03248492
- Testing
- DS-8201a
- Where
- 99 sites in United States, Belgium and 7 more
- Volunteers
- 253 people
- Sponsor
- Daiichi Sankyo
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic…
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT07545811
- Testing
- JANX014
- Where
- 6 sites in United States
- Volunteers
- 43 people
- Sponsor
- Janux Therapeutics
Prostate Cancer
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
Enthuse M1 is a large phase III clinical trial studying the safety and efficacy of ZD4054 (Zibotentan) in patients with hormone resistant prostate cancer and bone metastases.
- Trial name
- ENTHUSE M1 (NCT00554229)
- Testing
- ZD4054
- Where
- 197 sites in United States, Argentina and 29 more
- Volunteers
- 896 people
- Sponsor
- AstraZeneca
Breast Cancer
A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy
The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of GDC-0810 compared with fulvestrant in postmenopausal women with advanced or metastatic estrogen receptor positive (ER+)/ human epidermal…
- Trial name
- HydranGea (NCT02569801)
- Testing
- Fulvestrant, GDC-0810
- Where
- 44 sites in United States, Australia and 4 more
- Volunteers
- 71 people
- Sponsor
- Genentech, Inc.
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug[s]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab.
- Trial name
- NCT03972657
- Testing
- REGN5678, Cemiplimab
- Where
- 26 sites in United States, South Korea
- Volunteers
- 345 people
- Sponsor
- Regeneron Pharmaceuticals
Prostate Cancer
A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617
The aim of this study was to evaluate patient characteristics, treatment patterns, prostate-specific antigen (PSA) reduction, and overall survival (OS) of prostate cancer patients treated with 177-Lutetium-Prostate-Specific…
- Trial name
- NCT07450157
- Where
- United States
- Volunteers
- 6,448 people
- Sponsor
- Novartis Pharmaceuticals
MCRPC
A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
This is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical study evaluating the efficacy and safety of HC-1119 soft capsules versus placebo in mCRPC patients who have failed or become intolerant to the…
- Trial name
- NCT03851640
- Testing
- HC-1119
- Where
- China
- Volunteers
- 417 people
- Sponsor
- Hinova Pharmaceuticals Inc.
Metastatic Castration Resistant Prostate Cancer
A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics
This is a phase I study evaluating HC-1119 single-dose pharmacokinetics and effect of food on its pharmacokinetics in healthy Chinese adults.
- Trial name
- NCT03776968
- Testing
- HC1119
- Where
- China
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Hinova Pharmaceuticals Inc.
Prostate Cancer
Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer
The purpose of this trial is to study KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen.
- Trial name
- NCT00104130
- Testing
- KOS-862
- Where
- 9 sites in United States
- Volunteers
- 53 people
- Sponsor
- Bristol-Myers Squibb
HPV Associated Cancers
Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer
This is an open-label, non-randomized, Phase I, dose escalation/dose expansion study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers.
- Trial name
- NCT05826275
- Testing
- TGN-S11, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Toragen, Inc.